Choate Investment Advisors Has $2.03 Million Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Choate Investment Advisors decreased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 1.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,352 shares of the financial services provider’s stock after selling 250 shares during the quarter. Choate Investment Advisors’ holdings in iShares Biotechnology ETF were worth $2,030,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of the business. Cullen Frost Bankers Inc. grew its position in iShares Biotechnology ETF by 1.5% in the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after purchasing an additional 82 shares during the period. Transcend Capital Advisors LLC grew its position in iShares Biotechnology ETF by 0.8% in the 4th quarter. Transcend Capital Advisors LLC now owns 10,958 shares of the financial services provider’s stock valued at $1,449,000 after purchasing an additional 92 shares during the period. Chicago Partners Investment Group LLC grew its position in iShares Biotechnology ETF by 2.5% in the 4th quarter. Chicago Partners Investment Group LLC now owns 3,783 shares of the financial services provider’s stock valued at $510,000 after purchasing an additional 94 shares during the period. WealthCare Investment Partners LLC lifted its stake in iShares Biotechnology ETF by 0.9% during the 4th quarter. WealthCare Investment Partners LLC now owns 10,348 shares of the financial services provider’s stock valued at $1,375,000 after acquiring an additional 96 shares in the last quarter. Finally, Capital Investment Advisors LLC boosted its holdings in iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock worth $1,381,000 after acquiring an additional 99 shares during the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

IBB opened at $134.19 on Friday. The company has a market capitalization of $6.34 billion, a price-to-earnings ratio of 24.52 and a beta of 0.84. The firm’s fifty day moving average price is $136.25 and its two-hundred day moving average price is $139.81. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.